snipr001
Gene therapyexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 24, 2022 (NCT05277350)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Escherichia coliINHIBITOR
Escherichia coli inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06938867 | Phase 1/Phase 2 (Phase 2) | Feb 25, 2025 | Bill and Melinda Gates Foundation, Department of Health and Human Services, German Federal Ministry of Education and Research, SNIPR Biome Aps., Wellcome Trust |
| NCT05277350 | Phase 1 | Mar 24, 2022 | Department of Health and Human Services, SNIPR Biome Aps., Wellcome Trust |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Department of Health and Human Services | Government | 2 | 0 | 2 | 2022 |
| SNIPR Biome Aps. | For profit | 2 | 2 | 2 | 2022 |
| Wellcome Trust | Academic/Hospital | 2 | 0 | 2 | 2022 |
| Bill and Melinda Gates Foundation | Academic/Hospital | 1 | 0 | 1 | 2025 |
| German Federal Ministry of Education and Research | Government | 1 | 0 | 1 | 2025 |
5 organizations
Page 1 / 1